The INSTINCT-MB Project
Medulloblastoma is the most common malignant brain tumour in children, and it poses one of the greatest challenges in paediatric oncology. Despite advances in treatment, survival rates for children with high-risk subtypes of medulloblastoma, such as those driven by the MYC gene, have remained alarmingly low. The need for new and more effective treatments is urgent. In response to this challenge, the INSTINCT-MB project, led by Newcastle University, is pioneering new approaches to combat this deadly disease.
Understanding Medulloblastoma and Its Subtypes
Medulloblastoma is a type of embryonal tumour, which originates from the cells in the cerebellum—a part of the brain that controls balance and coordination. While medulloblastoma can affect children of all ages, it is most commonly diagnosed in those under the age of 10. The disease is divided into several molecular subtypes, each with different biological behaviours and prognoses. Among these, the subtype driven by the MYC gene is particularly aggressive and challenging to treat.
The MYC gene is a powerful oncogene that plays a critical role in cell growth and division. When it becomes overactive, it can drive the rapid proliferation of tumour cells, leading to the aggressive nature of MYC-amplified medulloblastomas. These tumours are often resistant to standard therapies, including surgery, radiation, and chemotherapy, resulting in poor outcomes for affected children.
In recent years, there has been a growing recognition of the need to develop targeted therapies that specifically address the unique characteristics of MYC-amplified medulloblastomas. This is where the INSTINCT-MB project comes in.
The INSTINCT-MB Project: A Collaborative Effort
The INSTINCT-MB project is a collaborative research initiative that brings together some of the UK’s leading cancer research institutions, including Newcastle University, the UCL Institute of Child Health, and The Institute of Cancer Research (ICR). The project is funded by several UK charities and it aims to develop new treatments for medulloblastoma, particularly for the high-risk groups with MYC-driven tumours.
One of the key objectives of the INSTINCT-MB project is to identify new drug targets and develop therapies that can effectively inhibit the growth of MYC-amplified medulloblastomas. To achieve this, researchers are employing a range of cutting-edge techniques, including high-throughput screening, genetic sequencing, and CRISPR-based gene editing.
Recent Breakthroughs and Ongoing Research
Since its inception, the INSTINCT-MB project has made several important discoveries that have advanced our understanding of medulloblastoma and opened new avenues for treatment. One of the most significant breakthroughs has been the identification of several potential drug targets specific to MYC-amplified medulloblastomas. These targets, which were discovered through extensive genetic screening and sequencing efforts, represent the first steps toward the development of therapies that could more effectively combat this aggressive cancer.
Researchers have also made progress in understanding how MYC-driven tumours evade the immune system, which has direct implications for the development of CAR-T cell therapy. By uncovering the mechanisms that these tumours use to suppress immune responses, the project is laying the groundwork for engineering CAR-T cells that can overcome these defences and effectively target the cancer cells.
Additionally, the INSTINCT-MB project has been pioneering the use of combination therapies—treatments that use more than one drug or therapeutic approach simultaneously. These combination therapies aim to target multiple pathways that the tumour cells rely on for survival, thereby increasing the chances of successfully treating the cancer. Early studies have shown that combining targeted therapies with existing treatments such as radiation or chemotherapy can significantly enhance their effectiveness, offering new hope for children with high-risk medulloblastomas.
The project has also been instrumental in advancing the use of personalised medicine for medulloblastoma patients. By integrating genetic data from tumour samples with clinical information, the researchers are developing more accurate predictive models that can inform treatment decisions. This personalised approach ensures that each child receives the therapy that is most likely to be effective for their specific type of tumour, reducing the likelihood of unnecessary side effects and improving overall outcomes.
Challenges and Future Directions
Despite the significant progress made by the INSTINCT-MB project, several challenges remain. One of the biggest challenges is the need to translate the findings from the laboratory into treatments that can be safely and effectively used in patients. This process, known as translational research, often requires additional studies and clinical trials to ensure that the new therapies are both effective and safe for children.
Another challenge is the complexity of medulloblastoma itself. The disease is highly heterogeneous, meaning that even within the same subtype, there can be significant differences in how tumours behave and respond to treatment. This heterogeneity makes it difficult to develop a one-size-fits-all approach to treatment and highlights the need for personalised medicine.
Looking to the future, one of the key priorities is to develop more sophisticated models of medulloblastoma that better reflect the complexity of the disease. These models, which may include 3D cell cultures and patient-derived xenografts, will be used to test new therapies and improve our understanding of how the cancer develops and progresses.
Finally, the INSTINCT-MB project will continue to focus on the development of biomarkers—molecular indicators that can be used to predict how a tumour will respond to treatment. Biomarkers are essential for the development of personalised medicine, as they allow clinicians to tailor treatments to the specific characteristics of a patient’s tumour. By identifying and validating new biomarkers, the project aims to make personalized medicine a reality for all children with medulloblastoma.
At Joss Searchlight, we are deeply committed to supporting research that has the potential to save lives and improve outcomes for children with brain cancer. The INSTINCT-MB project represents exactly the kind of innovative, collaborative effort that we believe is essential to making progress in this challenging field.
The progress made by the INSTINCT-MB project is a testament to what can be achieved when researchers, clinicians, and charities come together with a shared goal. However, this progress would not be possible without the support of individuals and organisations who believe in the importance of brain cancer research. Your donations to Joss Searchlight help fund the groundbreaking research that is making a real difference in the fight against medulloblastoma. Please consider making a donation today. Together, we can continue to drive forward the research that will save lives and bring hope to families affected by brain cancer.
Help us find a cure for rare brain tumours and give support today
